Current Report · Items 5.08, 8.01 · 8-K
KALA BIO, Inc.
KALANASDAQEQUITYCurrent
Shareholder Director Nominations · Other Events
Item 5.08 Shareholder Director Nominations. To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
Filed Sep 9, 2026Accepted Sep 9, 2026, 5:06 PM EDTCIK 1479419Accession 0001829126-26-009946
Company context
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors. KPI-012 received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing.
Current securities
Disclosure sections
Items 5.08, 8.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 5.08Item 5.08 - Shareholder Nominations
Item 5.08 Shareholder Director Nominations.
To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 9, 2026, the Board of Directors of KALA BIO, Inc. (the “Company”) established November 3, 2026 as the date of the Company’s next annual meeting of stockholders (the “Annual Meeting”). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the Annual Meeting in the Company’s proxy statement for the Annual Meeting.
Because the date of the Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company’s last annual meeting of stockholders, the Company has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (“Rule 14a-8”) for inclusion in the Company’s proxy materials relating to the Annual Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company’s Secretary at the principal executive offices of the Company by September 19, 2026, which the Company has determined to be a reasonable time before the Company’s proxy materials are due to be printed and sent. Such proposals must also comply with the Company’s Third Amended and Restated By-Laws (the “By-Laws”) and the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in proxy materials, and any such proposal may be omitted if not in compliance with applicable requirements.
The address of the Company’s principal executive offices is 1167 Massachusetts Avenue, Arlington, Massachusetts 02476.
Stockholders wishing to nominate a director or propose matters to be considered at the Annual Meeting in the manner contemplated by the By-Laws must submit timely notice to the Company in order for such matters to be considered at the Annual Meeting. Because the date of the Annual Meeting will be advanced by more than 30 days from the first anniversary of the Company’s last annual meeting of stockholders, in accordance with Sections 1.10(b) and 1.11(b) of the By-Laws, such notice must be received by the Company’s Secretary at the address above by September 19, 2026 (which is the 10th day following the day on which public announcement of the date of the Annual Meeting was first made by the Company). Such proposals must also comply with all other requirements set forth in the By-Laws and other applicable laws.